

APA Official Actions

Position Statement on Access to Second-Generation Antipsychotic Medications

Approved by the Board of Trustees, December 2025

Approved by the Assembly, November 2025

© Copyright 2025, American Psychiatric Association. All rights, including for text and data mining (TDM), Artificial Intelligence (AI) training, and similar technologies, are reserved.

"Policy documents are approved by the APA Assembly and Board of Trustees. . . These are . . . position statements that define APA official policy on specific subjects. . ." – *APA Operations Manual*

Issue:

Despite strong clinical and research evidence, effective treatments for psychosis spectrum-related disorders via second-generation antipsychotics are not always made available as first line treatments. This current lack of access to effective and evidence-based treatments has negative impacts on clinical outcomes, public health, and health care financing.

It is the position of APA that:

Second-generation antipsychotic medications be made available as first-line treatments for clear, evidence-based indications under the oversight of physician-led medical teams and with safeguards for diagnostic accuracy, informed consent, and ongoing monitoring throughout all systems of care.